Regiospecific Chlorination of (S)- β -Tyrosyl-S-Carrier Protein Catalyzed by SgcC3 in the Biosynthesis of the Enediyne Antitumor Antibiotic C-1027

Shuangjun Lin,¹ Steven G. Van Lanen,¹ and Ben Shen^{1,2,3,*}

¹Division of Pharmaceutical Sciences, ²University of Wisconsin National Cooperative Drug Discovery Group, and ³Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53705, USA.

*To Whomcorrespondence should be addressed: Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Ave., Madison, WI 53705. Tel.: (608) 263-2673; Fax: (608) 262-5345; E-mail: <u>bshen@pharmacy.wisc.edu</u>

Supporting Information

General information. Coenzyme A (CoA), adenosine triphosphate disodium salt (ATP), flavin adenine dinucleotide disodium salt (FAD), flavin adenine mononucleotide sodium salt dihydrate (FMN), β-nicotinamide adenine dinuceotide reduced disodium salt (NADH), tris(2carboxyethyl)phosphine hydrochloride (TCEP), were purchased from Sigma-Aldrich (St. Louis, MO). IPTG and dithiothreitol was purchased from Research Products International Corp. (Mt. Prospect, IL). The starting materials for the synthesis of β -amino acid analogues including 3-3-chloro-4-hydroxy-5-methoxybenzaldehyde, chloro-4-hydroxybenzaldehyde, 3-bromo-4hydroxybenzaldehyde, 3,4-dibenzyloxybenzaldehyde, boron tribromide and palladium (10 wt. %) on activated carbon were purchased from Sigma-Aldrich and used without further purification. (S)-3-Amino-3-(4-hydroxyphenyl)-propionic acid [(S)- β -tyrosine] and (R)-3amino-3-(4-hydroxyphenyl)-propionic acid $[(R)-\beta$ -tyrosine] were from PepTech Corporation (Burlington, MA). Media components and all other chemicals were from Fisher Scientific (Fairlawn, NJ). Electrospray ionization-mass spectrometry (ESI-MS) was measured with an Agilent 1100 HPLC-MSD SL ion trap mass spectrometer (Agilent Technologies, Inc., Santa Clara, CA). NMR was recorded on a Varian Unity Inova 400 or 500 MHz NMR Spectrometer (Varian, Inc., Palo Alto, CA). PCR was performed with a PerkinElmer GeneAmp 2400 (PerkinElmer Life And Analytical Sciences, Inc., Waltham, MA).

Synthesis of 3-chloro- β -tyrosine. Synthesis of 3-chloro- β -tyrosine was achieved using the method reported by Weaver.¹ 3-Chloro-4-hydroxybenzaldehyde (76 mg) was refluxed with 1 equivalent of malonic acid (51 mg) and 2 equivalents of ammonium acetate (76 mg) in 5 mL of ethanol for 7 hrs under an argon atmosphere. The reaction mixture was adjusted to pH 4 and separated on a strongly acidic cation-exchange column (Dowex® 50W-X8). The product, 3-chloro- β -tyrosine, was eluted with 1% ammonium hydroxide. Solvent was removed through evaporation under reduced pressure, and the residue was dissolved in distilled water and further purified by C18-reverse phase chromatography. ¹H NMR (D₂O - CF₃CO₂D, 400 MHz): δ 7.08 (d, *J* = 2.4 Hz, 1H), 6.87 (dd, *J* = 8.8, 2.4 Hz, 1H), 6.65 (d, *J* = 8.4 Hz, 1H), 4.30 (t, *J* = 7.2 Hz,

Hβ, 1H), 2.77 (dd, J = 17.2, 7.6 Hz, Hα, 1H), 2.66 (dd, J = 17.2, 6.4 Hz, Hα, 1H). ¹³C NMR (D₂O - CF₃CO₂D, 100 MHz): δ 173.1 (C=O), 152.8 (ArC), 129.2 (ArC), 128.0 (ArC), 127.1 (ArC), 120.7 (ArC), 117.6 (ArC), 50.7 (C_β), 37.5 (C_α). ESI-MS *m*/*z* 216.0 and 218.0 for [M + H]⁺ and *m*/*z* 213.9 and 216.0 for [M - H]⁻; calculated for C₉H₁₀NO₃Cl, 215.0 and 217.0. HRMS-ESI-MS *m*/*z* 214.0263 for [M - H]⁻; calculated [M - H]⁻ for C₉H₁₀NO₃Cl, 214.0271.

Synthesis of 3-bromo-β-tyrosine. 3-Bromo-β-tyrosine was prepared as described above using 3bromo-4-hydroxybenzaldehyde as starting material. ¹H NMR (D₂O - CF₃CO₂D, 400 MHz): δ 7.60 (d, J = 2.4 Hz, 1H), 7.27 (dd, J = 8.4, 2.4 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 4.65 (t, J = 7.2Hz, 1H), 3.11 (dd, J = 17.2, 8.0 Hz, 1H), 3.00 (dd, J = 17.6, 6.8 Hz, 1H). ¹³C NMR (D₂O -CF₃CO₂D, 100 MHz): δ 173.2 (C=O), 153.8 (ArC), 132.3 (ArC), 128.7 (ArC), 128.1 (ArC), 117.2 (ArC), 110.1 (ArC), 50.8 (C_β), 37.8 (C_α). ESI-MS m/z 260.0 and 262.0 for [M + H]⁺ and m/z 243.0 and 245.0 for [M + H – NH₃]⁺; calculated for C₉H₁₀NO₃Br, 259.0 and 261.0. HRMS-ESI-MS m/z 257.9757 for [M - H]⁻; calculated [M - H]⁻ for C₉H₁₀NO₃Br, 257.9766.

Synthesis of 3-hydroxy-β-tyrosine. 3-Hydroxyl-β-tyrosine was prepared as described above using 3,4-dibenzyloxybenzaldehyde as a starting material. After purification with silica chromatography, the protecting groups were removed by catalytic hydrogenation with 10% Pd/C. Benzyl alcohol was removed using C18-reverse phase chromatography to yield a light brown powder. ¹H NMR (D₂O, 400MHz): δ 6.74-6.85 (m, 3H), 4.42 (t, *J* = 6.8 Hz, H β , 1H), 2.79 (dd, *J* = 15.6, 8.0 Hz, H α , 1H), 2.69 (dd, *J* = 16.0, 6.4 Hz, H α , 1H). ¹³C NMR (D₂O 125 MHz): δ 177.9 (C=O) 145.5 (ArC), 145.6 (ArC), 128.7 (ArC), 119.4 (ArC), 116.6 (ArC), 115.0 (ArC), 52.7 (C_β), 40.9 (C_α). ESI-MS *m*/*z* 198.0 for [M + H]⁺ and *m*/*z* 195.9 for [M - H]⁻, calculated for C₉H₁₀NO₄, 197.0. HRMS-ESI-MS *m*/*z* 196.0610 for [M - H]⁻; calculated [M - H]⁻ for C₉H₁₀NO₄, 196.0603.

Synthesis of 3-chloro-5-hydroxy- β -tyrosine. 3-Chloro-4,5-dihydroxybenzaldehyde was prepared by following the procedure reported by Hua and co-workers². To a solution containing 2.0 g of 3-chloro-4-hydroxy-5-methoxybenzaldehyde in 20 mL of dried dichoromethane was added 1.2 mL of boron tribromide. The resulting solution was stirred at 0 °C for 30 min, heated to room temperature, and incubated at room temperature for an additional 3 hrs. After removal of a trace amount of unreacted 3-chloro-4-hydroxy-5-methoxybenzaldehyde by flash silica column chromatography, the 3-chloro-4,5-dihydroxybenzaldehyde product was added to 40 mL anhydrous ethanol under argon, and was refluxed with ammonium acetate and malonic acid until all 3-chloro-4,5-dihydroxy-benzaldehyde reacted as judged by thin layer chromatography (TLC). 3-Chloro-5-hydroxy-\beta-tyrosine was purified by C18-reverse phase chromatography using standard conditions. ¹H NMR (D₂O, 500 MHz): δ 7.04 (d, J = 2.5 Hz, 1H), 6.92 (d, J = 2.5 Hz, 1H), 4.60 (t, J = 7.5 Hz, 1H), 3.04 (dd, J = 17.0, 8.0 Hz, 1H), 2.95 (dd, J = 17.0, 6.5 Hz, 1H). ¹³C NMR (D₂O, 125 MHz): δ 175.1 (C=O), 146.1 (ArC), 141.8 (ArC), 128.6 (ArC), 121.8 (ArC), 120.2 (ArC), 113.6 (ArC), 51.6 (C_{β}), 38.8 (C_{α}). ESI-MS m/z 232.1 and 234.1 for [M+H]⁺ and m/z 230.1 and 232.1 for [M-H]⁻; calculated for C₉H₁₀NO₄Cl, 231.0 and 233.0. HRMS-ESI-MS m/z 230.0211 for [M - H]; calculated [M - H] for C₉H₁₀NO₄Cl, 230.0220.

<u> </u>	
Name of primer	Sequence ^a
SgcC2 forward	5'-GACGACGACAAG <u>ATG</u> TCCACCGTTTCCGAC-3'
SgcC2 reverse	5'-GAGGAGAAGCCCGG <u>TCA</u> CTGCGTTCCGGAGCC-3'
SgcC3 forward	5'-GGTATTGAGGGTCGC <u>ATG</u> GACGTGTCAGCGCAGTAC-3'
SgcC3 reverse	5'-AGAGGAGAGTTAGAG <u>TCA</u> GGACCGCGCACCGGG-3'
SgcE6 forward	5'-GGTATTGAGGGTCGCATGAGTCCGATCATCGCTCC-3'
SgcE6 reverse	5'-AGAGGAGAGTTAGAG <u>TCA</u> TGCCGCCCTTCCTTCG-3'
E.Coli Fre forward	5'-GGTATTGAGGGTCGC <u>ATG</u> ACAACCTTAAGCTGTAAAG-3'
E.Coli Fre reverse	5'-AGAGGAGAGTTAGAG <u>TCA</u> GATAAATGCAAACGCATCG-3'
^a The stort (ATC) and ston (TCA) as done are up dealined	

Table S1. Primers used for amplification of the sgcC2, sgcC3, sgcE6, and E. coli fre genes for heterologous expression.

^aThe start (ATG) and stop (TGA) codons are underlined.

Figure S1. HPLC chromatograms for determination of the FAD cofactor non-covalently bound to SgcC3: (I) FAD (\blacklozenge) standard; (II) supernatant from denatured SgcC3 by heat; (III) FMN (\bullet) standard.



Figure S2. ESI-MS spectra of (*S*)-3-chloro- β -tyrosine (**13**) released from hydrolysis of (*S*)-3-chloro- β -tyrosyl-S-SgcC2 (**10**): (**A**) in positive mode showing [M + H]⁺ ions at m/z 216 and 218 and [M + H – NH₃]⁺ ions at m/z 199 and 201 and (B) in negative mode showing [M - H]⁻ ions at m/z 214 and 216.



Figure S3. Relative activity of SgcC3 as a halogenase determined in 50 mM sodium acetate, pH 5.0 - 5.5, 50 mM sodium phosphate, pH 6.0 - 8.0, and Tris-HCl, pH 8.5 - 9.0.



References

- (1) Tan, C. Y. K.; Weaver, D. F. Tetrahedron 2002, 58, 7449-7461.
- (2) Hua, T. C.; Huang, X.; Chen, Y.; Battina, S. K.; Tamura, M.; Noh, S. K.; Koo, S. I.; Namatame, I.; Tomoda, H.; Perchellet, E. M.; Perchellet, J.-P. J. Org. Chem. 2004, 69, 6065-6078.